**Occurrence of Linezolid induced thrombocytopenia and its association with the risk factors: a review article**

Radha A.1*, Anuradha H. V.1, Radhika K.2

1Department of Pharmacology,  
2Department of Community Medicine, M.S. Ramaiah Medical College, Bangalore, Karnataka, India

**ABSTRACT**

Linezolid is the oxazolidinone group of antibiotic with wide range of activity against the gram positive bacteria including methicillin resistant staphylococcus aureus and penicillin resistant pneumococci and vancomycin resistant enterococci. Patients who are on linezolid were reported to have reversible myelosuppression especially thrombocytopenia and anaemia. Since there are less number of studies regarding the occurrence of thrombocytopenia and the risk factors associated with it, this study was undertaken to evaluate the occurrence of linezolid induced thrombocytopenia and its association with risk factors. It was a systematic review with synthesis of available literature in English language. Articles were retrieved using search terms included “linezolid”, “and”, “or”, “thrombocytopenia” from Clinical key and PubMed, published during 2000 - 2017. Out of 16 studies retrieved, only 7 studies were analysed based on inclusion and exclusion criteria; of them, 3 were found to be prospective and retrospective cohort each and only one was retrospective cross-sectional study. The occurrence of linezolid induced thrombocytopenia range from 18-50% with normal renal function and 57% of incidence associated with renal insufficiency patients. The risk factors were found to be dose of linezolid >18-27mg/kg, body weight of subjects <55kg, creatinine clearance <88.39 to 60ml/min/1.73m² and baseline platelet count <200*10³/mm³, serum albumin concentration, serum creatinine, concomitant caspofungin therapy and duration of linezolid therapy.

**Keywords:** Baseline platelet count, Linezolid, Occurrence, Oxazolidinone, Risk factors, Thrombocytopenia

**INTRODUCTION**

Linezolid is the Oxazolidinone group of antibacterial agent with wide range of activity against the gram positive bacteria including Methicillin Resistant Staphylococcus Aureus (MRSA) and penicillin resistant pneumococci and vancomycin resistant enterococci.1 It disrupts bacterial growth by inhibiting the initiation process of protein synthesis by binding to domain V of the 23S ribosomal RNA of the 50S subunit of bacterial ribosomes.2,3 Linezolid site of inhibition occurs earlier in the initiation process than other protein synthesis inhibitors like chloramphenicol, clindamycin, aminoglycosides and macrolides that interfere with the elongation process.4 The site of inhibition is specific to linezolid, so cross-resistance to other protein synthesis inhibitors has not yet been reported. It may also suppress virulence factor expression and decrease toxin production in gram-positive pathogens.5 It has 100% bioavailability by oral because it has high water solubility and robust tissue penetration.6 It is metabolized by liver into two primary oxidation products and 80% of the drug was excreted through kidney and 20% in the feces respectively.7,8 It’s half-life...
approximates 5-7 hrs and the dosing interval is 12 hrs. Patients who are on treatment with linezolid were reported to have reversible myelosuppression, especially thrombocytopenia and anaemia. Thrombocytopenia has the highest incidence of 30% and anaemia with 2.8-47.3% among patients receiving linezolid. The risk factors for linezolid treatment are thrombocytopenia, renal insufficiency, chronic liver disease, respiratory tract infection, duration of linezolid therapy, baseline platelet count, low body weight and the use of vancomycin. Hence, patients should be observed for myelosuppression during linezolid treatment because it can occasionally result in discontinuing the treatment. As there were limited studies in this regard, we sought to review and evaluate the occurrence of linezolid induced thrombocytopenia and the associated risk factors.

REVIEW OF LITERATURE

Search strategy

Authors carried out a systematic review with synthesis of available literature in English language. Articles were retrieved using search terms included “linezolid”, “and”, “or” “thrombocytopenia” from Clinical key and PubMed published from 2000 to 2017. Out of 16 studies retrieved, only 7 studies were analysed based on inclusion and exclusion criteria; of which 3 each were prospective and retrospective cohort and only one was retrospective cross sectional study.

Inclusion criteria

Authors have been included the studies in which patients aged ≥18 years and on linezolid therapy more than 3 days.

Exclusion criteria

Studies included patients who had severe thrombocytopenia (<50*10⁹/L) before linezolid treatment, bleeding disorder, known liver disease, coagulopathies, on any anticancer drugs during linezolid therapy, platelet count not recorded before or after linezolid therapy, suffering from cancer, missed clinical data and case reports were excluded.

Data extraction

Authors discarded irrelevant studies after screening all titles and abstracts and evaluated the full texts of the remaining studies to determine the inclusion and exclusion criteria.

The entire selection process is summarized in the PRISMA flow chart (Figure 1). Demographic, epidemiological, clinical variables were collected in detail including epidemiological design of the study, location of the study, age of the enrolled patients, dose and duration of the drug, baseline platelet count, creatinine clearance, the risk factors associated with thrombocytopenia and occurrence of thrombocytopenia.

DISCUSSION

Out of total seven articles reviewed; four studies were performed in Japan, two in China, one each in Taiwan and Italy. Thrombocytopenia definition used varied among the studies; thrombocytopenia is considered, if there was >25% reduction from the baseline platelet count with final platelet count <1 lakh/mm³, >25% reduction from the baseline platelet count only; ≥30% from the baseline platelet count; ≥50% from the baseline platelet count (Table 1). Two studies which defined thrombocytopenia as ≥25% reduction from the baseline platelet count and final platelet count <1 lakh/mm³ has shown the occurrence ranging from 18 - 48% with mean age range of 66 to 83 years with mean dose of 24mg/kg in one study and 600 mg BD in other study and mean duration of 12 to 14 days. Another two studies with thrombocytopenia definition >25% reduction from the baseline platelet count showed the occurrence of about 16.6-50% with mean age of 50-61 years with a mean dose of 17-20mg/kg in one study and 600mg BD in another study for mean duration of 8 days -12 weeks.

Study with definition of thrombocytopenia >30% from the baseline platelet count showed occurrence of 48.4% with mean age range of 61-67 years with mean dose of 21mg/kg with mean duration of 11-16 days.

Study which has considered thrombocytopenia >50% from the baseline platelet count in another study, had an occurrence of 48% with mean age range of 61-67 years, mean dose of 19-23mg/kg and median duration of 14 days. In one study where the thrombocytopenia occurrence has been analysed based on presence or absence of renal insufficiency showed 57% and 33% with and without renal insufficiency with mean age of 68 years with dose of 600mg BD and mean duration of 10 days.
Table 1: Characteristics of the studies.

| Authors and Place of study | Type of study and Sample size (N) | Thrombocytopenia (TP) definition | With/without TP | Age (mean) years | Number of subjects (N) | Dose of linezolid (Mean±SD) mg/kg body wt. | Duration of linezolid (Mean) day/week | Occurrence (percentage) | Baseline platelet count (10^9/mm^3) | CrCl (ml/min) |
|---------------------------|---------------------------------|---------------------------------|-----------------|-----------------|---------------------|---------------------------------------------|-------------------------------------|------------------------|-------------------------------|--------------|
| Niwa.T et al\(^1\) Japan  | Prospective 50                  | >25% and <1 lakh/mm\(^3\)      | With TP         | 66              | 9                   | 24.3±2.1                                    | 12 days                        | 18%                    | 179±96                       | 64.5±60.4      |
|                           |                                 |                                 | Without TP      | 62              | 41                  | 20.4±4.2                                    | 12 days                        | 274±143                | 103.6±89.0                   |              |
| Chen.C et al\(^1\) China  | Retrospective 254               | >25% reduction in baseline     | With TP         | 61.36           | 69                  | 19.99±4.18                                  | 10.31±5.64 days               | 50%                    | 212.5±76.96                  | 87.67±59       |
|                           |                                 |                                 | Without TP      | 56.83           | 185                 | 17.83±4.39                                  | 8.55±5.54 days                | 31%                    | 224.71±72.85                 | 106.90±58.28  |
| Bi L et al\(^1\) China    | Retrospective 50                | >25% and <1 lakh/mm\(^3\)      | With TP         | 83±9            | 24                  | 600mg BD*                                    | 14±2 days                     | 48%                    | 204±118                      | 46±36         |
|                           |                                 |                                 | Without TP      | 80±11           | 26                  | 600mg BD*                                    | 12±2 days                     | 31%                    | 272±101                      | 60±43         |
| Garazzino S et al\(^1\) Italy | Prospective 31               | >25% reduction in baseline     | With TP         | 50.5            | 2                   | 600mg BD*                                    | 12 weeks                      | 16.6%                  | 220                          |              |
|                           |                                 |                                 | Without TP      | 29              |                     | 600mg BD*                                    |                            |                        |                              |              |
| Natsumoto B et al\(^2\) Japan | Retrospective 101            | >50% reduction in baseline     | With TP         | 67.83           | 42                  | 23.47±5.1                                   | 14(3-67) days**               | 48%                    | 289.98                       | 67.2±41.57     |
|                           |                                 |                                 | Without TP      | 61.76           | 59                  | 19.9±5.3                                    | 14(1-63) days**               |                        | 249.63                       | 181.85±156.9  |
| Hanai Y et al\(^2\) Japan | Retrospective 221             | >30% reduction in baseline     | With TP         | 67.6±13.1       | 107                 | 21.8±2.4                                    | 16±6 days                     | 48.4%                  | 239.8±133.2                  | 35±24.3       |
|                           |                                 |                                 | Without TP      | 61.7±15.2       | 114                 | 21.0±2.3                                    | 11±6.9 days                   |                        | 239.0±140.0                  | 78±34.6       |
| Wu H et al\(^3\) Taiwan  | Prospective 13                 | >25% reduction in baseline     | With TP         | 68.3±15.0       | 6                   | 600mg BD*                                    | 10±9.5 5.1 days               | 33% in normal renal function 57% in renal pts | 335.6±147.4 | No value |

TP: thrombocytopenia
*Standard dose was administered; ** Median duration of linezolid was documented instead of mean.

Table 2: Characteristics of risk factors in this study.

| Studies | Baseline platelet count (<200*10^9/mm^3) | Creatinine clearance (ml/min) | Hemodialysis | Dose mg/kg | Body weight (<55kg) | Duration (days) | Serum albumin (g/l) | Caspofungin | Serum creatinine (mg/dl) |
|---------|----------------------------------------|-----------------------------|---------------|-----------|---------------------|----------------|---------------------|-------------|------------------------|
| Niwa T et al\(^1\) | OR - 24.9 p - 0.024 | >22 O - 9.55 p - 0.010 | OR - 33.2 p - 0.012 |
| Chen C et al\(^1\) | NA | OR - 0.10 p - 0.04 | >18 OR - 1.12 p - 0.001 | NA | OR - 0.95 p - 0.03 | OR - 2.81 p - 0.01 | Adjusted OR - 1.51 p - 0.04 |
| Natsumoto B et al\(^2\) | Adjusted CrCl -52.2 | OR - 0.94 p - 0.001 | Adjusted OR - 3.32 p - 0.011 | Adjusted OR - 1.14 p - 0.001 | 14.7 days | Adjusted OR - 1.14 p - 0.001 |

OR - odd’s ratio; NA- Not available; p - p value.
Among seven studies, only four have evaluated risk factors for linezolid induced thrombocytopenia (Table 2), in one study by Natsumoto et al, serum creatinine and Dose Per Kg bodyweight per Day (DPKD, mg/kg/day) has been identified as risk factor.\(^1\)\(^6\)\(^7\)\(^11\) The adjusted odds ratio with 95% confidence interval for serum creatinine (mg/dl) and DPKD, were 1.51 (1.01-2.50) and 1.14 (1.05-1.26) respectively by Bi and multivariate logistic regression.

In a study conducted by Hanai Y et al, multiple logistic regression analysis identified creatinine clearance (CrCl), hemodialysis and duration of linezolid therapy with adjusted odds ratio (OR) of 0.94 (0.92-0.95, \(p<0.001\)), 3.32 (1.14-9.67, \(p<0.011\)) and 1.14 (1.07-1.21, \(p<0.001\)) respectively with 95% CI as the risk factors for linezolid induced thrombocytopenia. It was found that the incidence of thrombocytopenia was less (9.1%) in normal subjects compared to renal insufficiency subjects (18.5 - 81.4%), the discontinuation rate was higher in renal insufficiency compared (7.4% -62.5%) to normal subjects (2.3%) and the onset of thrombocytopenia ranging from 7-12 days.\(^2\) It was also observed that the incidence of anaemia was 8.6-43.5% with linezolid duration ranged from 7-10 days and there was no discontinuation of the therapy due to anaemia.

Study by Niwa et al, depicts daily dose >22mg/kg and body weight <55kg with odds ratio (OR) of 9.55 with 95%CI (1.72-53.1, \(p<0.010\)) and baseline platelet count of <20\(^*\)10\(^3\)/mm\(^3\) with OR of 6.20 (1.30-29.5, \(p<0.022\)) respectively as risk factors by univariate logistic regression and they also observed that dose adjustment of linezolid with one of the risk factor had prolonged onset of thrombocytopenia without affecting efficacy.\(^1\) The occurrence of thrombocytopenia increased from 18-72% when the DPKD and body weight of the patients increased from <17 to >27mg/kg and >70kg to <45kg respectively.

In retrospective cross-sectional Chen c et al study, creatinine clearance (OR-0.99), serum albumin concentration, daily dosage and caspofungin therapy were the risk factors by using multivariate logistic regression analysis and ROC curves.\(^11\)

Few studies have reported that the mean area under the blood concentration time curve (AUC) of linezolid is high in >80yr old patient and bodyweight <40kg (811.3\(\mu\)g/hr/ml) when compared to <80yr and bodyweight >40kg (217.6\(\mu\)g/hr/ml).\(^10\) Further prevalence was 63.6% in AUC >800\(\mu\)g-hr/ml and 51.3% in AUC<800\(\mu\)g/hr/ml.\(^6\) Dong et al reported that high plasma concentration of linezolid is a risk factor.\(^11\) Very limited studies were available, so further studies should be conducted to evaluate the risk factors associated with linezolid induced thrombocytopenia with respect to drug-drug interactions with linezolid and association between the linezolid plasma concentration and occurrence of thrombocytopenia. The strength of the study was inclusion of both prospective and retrospective studies in-terms of evidence, gives good results and less bias. Study was unique in terms of the attempts made to draw some conclusion and evidence on the occurrence and the factors associated with it. Unfortunately, it was not possible to perform meta-analysis because of high level of heterogeneity (I² 48%) among the selected articles.

The limitations of the study were; power of the study was not mentioned in any of the articles, only English language articles were included, the definition of thrombocytopenia was different in each article & lastly, a limited number of studies were available for the review.

CONCLUSION

The occurrence of linezolid induced thrombocytopenia ranged from 18-50% and the associated risk factors were low creatinine clearance, hemodialysis, body weight <55kg, increase DPKD low baseline platelet count, increased serum creatinine, increased duration of linezolid therapy, serum albumin concentration and concomitant caspofungin therapy. Hence, adequate and frequent monitoring for blood counts is essential in patients on linezolid therapy.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Niwa T, Watanabe T, Suzuki A, Ohmori T, Tsuchiya M, Suzuki T et al. Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight. Diagnostic Microbiology and Infectious Disease. 2014;79(1):93-7.
2. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(4):7-15.
3. Miller M, Schimz K. Oxazolidinones: a novel class of antibiotics. Cellular and Molecular Life Sciences (CMLS). 1999;56(3-4):280-5.
4. Zahedi BA, Rahbar M, Yousefi M, Asgharzadeh M, Samadi KH. Linezolid: a promising option in the treatment of Gram-positives. J Antimicrob Chemother. 2016;72(2):354-64.
5. Gemmell C. Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother. 2002;50(5):665-72.
6. Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007-12.
7. Hanai Y, Matsuo K, Ogawa M, Higashi A, Kimura I, Hirayama S, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Inf Chemother. 2016;22(8):536-42.
8. Sweetman S. Antibacterial. In: Sweetman S, Blake P, editors. Martindale: The complete drug reference. 36th ed. London: Pharmaceutical Press; 2009:158-361.
9. MacDougall C. Protein synthesis inhibitors and miscellaneous antibacterial agents. In: brunton L, Dandan R, Knollman B, editors. Goodman and Gilman’s. The pharmacological basis of therapeutics. 13th ed. New York: Mc Graw Hill education; 2018:1049-1066.
10. Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Ant Chemoth. 2013;68(9):2128-33.
11. Chen C, Guo D, Cao X, Cai Y, Xu Y, Zhu M, et al. Risk Factors for Thrombocytopenia in Adult Chinese Patients Receiving Linezolid Therapy. Current Therapeutic Research. 2012;73(6):195-206.
12. Loo A, Gerzenshtein L, Ison M. Antimicrobial Drug-Induced Thrombocytopenia: A Review of the Literature. Seminars in Thrombosis and Hemostasis. 2012;38(08):818-29.
13. Bi L, Zhou S. Thrombocytopenia in Elderly Patients Who Received Intravenous Linezolid Therapy. Int J Gerontol. 2014;8(1):46-7.
14. Wu H, Wen C, Jang Y, Chen H. DI-056 Linezolid induced thrombocytopenia in a patient with renal insufficiency: A case report and a retrospective case study. European J Hos Pharm. 2016;23(1):A142.2-43.
15. Garazzino S, De Rosa F, Bargiacchi O, Audagnotto S, Maiello A, Di Perri G. Haematological safety of long-term therapy with linezolid. Int J Antimi Agent. 2007;29(4):480-3.

Cite this article as: Radha A, Anuradha HV, Radhika K. Occurrence of linezolid induced thrombocytopenia and its association with the risk factors: a review article. Int J Basic Clin Pharmacol 2018;7:2483-7.